BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33764163)

  • 1. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
    Mizukami T; Miyaji T; Narita Y; Matsushima T; Ogura T; Miyagaki H; Kawabata R; Horie Y; Kawaguchi T; Muro K; Hara H; Yamaguchi T; E Nakajima T
    Future Oncol; 2021 Jul; 17(19):2431-2438. PubMed ID: 33764163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
    Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
    BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
    Matsumoto H; Kawazoe A; Shimada K; Fukuoka S; Kuboki Y; Bando H; Kojima T; Ohtsu A; Yoshino T; Doi T; Shitara K
    BMC Cancer; 2018 Jan; 18(1):120. PubMed ID: 29385993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer.
    Nakajima TE; Kadowaki S; Minashi K; Nishina T; Yamanaka T; Hayashi Y; Izawa N; Muro K; Hironaka S; Kajiwara T; Kawakami Y
    Clin Cancer Res; 2021 Feb; 27(4):1029-1036. PubMed ID: 33262133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
    BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
    Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
    Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
    Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
    Parisi A; Cortellini A; Roberto M; Venditti O; Santini D; Dell'Aquila E; Stellato M; Marchetti P; Occhipinti MA; Zoratto F; Mazzuca F; Tinari N; De Tursi M; Iezzi L; Natoli C; Ratti M; Pizzo C; Ghidini M; Porzio G; Ficorella C; Cannita K
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2365-2373. PubMed ID: 31280347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
    Satake H; Sagawa T; Fujikawa K; Hatachi Y; Yasui H; Kotaka M; Kato T; Tsuji A
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):839-845. PubMed ID: 30167847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.
    Chen Y; Katayose T; Nagaoka S; Piao Y; Yamaguchi K; Asou H
    Gastric Cancer; 2021 Nov; 24(6):1320-1329. PubMed ID: 34050432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
    Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
    JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients.
    Kim J; Byeon S; Kim H; Yeo JH; Hong JY; Lee J; Lim HY; Kang WK; Kim ST
    Target Oncol; 2020 Apr; 15(2):203-209. PubMed ID: 32314267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study.
    Arai H; Kawahira M; Yasui H; Masuishi T; Muro K; Nakajima TE
    Int J Clin Oncol; 2021 Feb; 26(2):355-363. PubMed ID: 33063177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study.
    Longo F; Jorge M; Yaya R; Montes AF; Lago NM; Brozos E; Aparicio J; Quintero G; Ceballos E; Buxó E; Lopez AM; Pellón ML; Molina R; Diaz-Paniagua L; Cerdà P; Leiva PL; Carnicero AM; Cousillas A; Paris L; García-Paredes B; Romero C; Ortega M; Molero A; la Torre S; Jen MH; Díaz-Cerezo S
    Future Oncol; 2021 May; 17(14):1777-1791. PubMed ID: 33590772
    [No Abstract]   [Full Text] [Related]  

  • 18. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer.
    Natsume M; Shimura T; Iwasaki H; Okuda Y; Kitagawa M; Okamoto Y; Hayashi K; Kataoka H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1037-1046. PubMed ID: 30899983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.
    Kawai S; Fukuda N; Yamamoto S; Mitani S; Omae K; Wakatsuki T; Kato K; Kadowaki S; Takahari D; Boku N; Muro K; Machida N
    BMC Cancer; 2020 Apr; 20(1):338. PubMed ID: 32316940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial.
    Kim ST; Sa JK; Oh SY; Kim K; Hong JY; Kang WK; Kim KM; Lee J
    Genome Med; 2021 Jan; 13(1):11. PubMed ID: 33494793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.